Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?

British Journal of Clinical Pharmacology

Volumn 70, Issue 3, 2010, Pages 360-366

  Towse, Adrian ^a  

^a Office of Health Economics   (United Kingdom)

Author keywords

NICE; Pharmaceutical industry; Value based pricing

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG MARKETING; DRUG RESEARCH; GOVERNMENT; HEALTH CARE ACCESS; MEDICAL TECHNOLOGY; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; DRUG INDUSTRY; GOVERNMENT AGENCIES; GREAT BRITAIN; HUMANS; NATIONAL HEALTH PROGRAMS; PATIENT SATISFACTION; RELATIVE VALUE SCALES; RESEARCH;

EID: 77955761482     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03740.x     Document Type: Review

References (27)

1. The OFT Report. The pharmaceutical price regulation scheme. Office of Fair Trading. 2007. Available at http://www.oft.gov.uk/news/press/2007/29-07 (last accessed 27 July 2010).
2. Keyworth T, Yarrow G. Impact assessment review of the Office of Fair Trading's market study of the pharmaceutical price regulation. Scheme Regulatory Policy Institute. 2007. Available at http://www.rpieurope.org/Research/ PPRS%20Impact%20Assessment%20Review%20Web.pdf (last accessed 27 July 2010).
3. Life Sciences Blueprint. A statement from the Office for Life Sciences. HM Government. 2009. Available at http://www.dius.gov.uk/∼/media/ publications/O/ols-blueprint (last accessed 5 February 2010).
4. OLS. Life sciences 2010. Delivering the blueprint. Office for Life Sciences. 2010. Available at http://www.bis.gov.uk/policies/innovation/business- support/ols (last accessed 27 July 2010).
5. OLS, BIS Economics Paper No2. Life sciences in the UK-economic analysis and evidence for 'life sciences 2010: delivering the blueprint'. 2010. Available at http://www.berr.gov.uk/publications/economicsstatistics/ economicsdirectorate/page14636.html (last accessed 27 July 2010).
6. Sussex J, Garau M. Estimating pharmaceutical companies' value to the national economy: case study of the British Pharma Group. OHE Briefing. Office of Health Economics, 2007.
7. Green C. Considering the value associated with innovation in health technology appraisal decisions (deliberations): a NICE thing to do? Appl Health Econ Health Policy 2010 8 : 1 5.
8. Ferner RE, Hughes DA, Aronson JK. NICE and new: appraising innovation. BMJ 2010 340 : b5493.
9. Rawlins M, Barnett D, Stevens A. Pharmacoeconomics: NICE's approach to decision-making. Br J Clin Pharmacol 2010 70 : 346 349.
10. Culyer A. Deliberative Processes in Decisions about Health Care Technologies. London : Office of Health Economics, 2009.
11. Claxton K. OFT, VBP: QED? Health Econ 2007 16 : 545 558.
12. Claxton K, Buxton M, Culyer T, Walker S, Sculpher M. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 2008 336 : 251 254.
13. Towse A. If it ain't broken don't price fix it: the OFT and the PPRS. Health Econ 2007 16 : 653 665.
14. NICE. Scientific advice consultancy service. Available at http://www.nice.org.uk/aboutnice/scientificadvice/AboutScientificAdvice.jsp (last accessed 27 July 2010).
15. DLTR. Multi-criteria analysis manual. 2000. Available at http://iatools.jrc.ec.europa.eu/public/IQTool/MCA/DTLR-MCA-manual.pdf (last accessed 27 July 2010).
16. Walley T. Drugs, money and society (part II). Br J Clin Pharmacol 2010 70 : 342 345.
17. Department of Health and Ageing and Medicines Australia. Activity indicators for the pharmaceutical benefits scheme. Second report: 2004 to 2008. 2009. Available at http://medicinesaustralia.com.au/pages/page222.asp (last accessed 10 June 2010).
18. Department of Health. The 2009 pharmaceutical price regulation scheme. 2008. Available at http://www.dh.gov.uk/dr-consum-dh/groups/dh-digitalassets/ documents/digitalasset/dh-098498.pdf (last accessed 28 July 2010).
19. Department for Business Innovation and Skills. Final government response to recommendations aimed at government contained in the OFT report 'the pharmaceutical price regulation scheme'. 2009. Available at http://www.berr.gov. uk/files/file51657.pdf (last accessed 28 July 2010).
20. Department of Health. Pharmaceutical price regulation scheme: tenth report to parliament. 2009. Available at http://www.dh.gov.uk/dr-consum-dh/ groups/dh-digitalassets/@dh/@en/@ps/@sta/@perf/documents/digitalasset/dh-111291. pdf (last accessed 28 July 2010).
21. Moss L. New cancer drugs on NHS after price deal. The Scotsman. 2009. Available at http://news.scotsman.com/cancerresearch/New-cancer-drugs-on-NHS. 5808768.jp (last accessed 28 July 2010).
22. Towse A, Garrison L. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics 2010 10 : 93 102.
23. Thomson D. Position statement on 'risk sharing' schemes in oncology. Endorsed by BOPA (British Oncology Pharmacy Association). 2007.
24. Williamson S. A report into the uptake of patient access schemes in the NHS. Cancer Network Pharmacist Forum. 2009. Available at http://www.bopawebsite. org/tiki-download-file.php?fileId=626 (last accessed 28 July 2010).
25. Boggild M, Palace J, Barton P, Ben-Shlomo Y, Bregenzer T, Dobson C, Gray R. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. BMJ 2009 339 : b4677. doi:10.1136/bmj.b4677.
26. McCabe C, Chilcott J, Claxton K, Tappenden P, Cooper C, Roberts J, Cooper N, Abrams K. Continuing the multiple sclerosis risk sharing scheme is unjustified. Br Med J 2010 340 : c1786.
27. Breckenridge A, Walley T. Risk sharing and payment by results. Clin Pharmacol Ther 2008 83 : 666 667.